Eli Lilly
1,516 hedge funds and large institutions have $83.5B invested in Eli Lilly in 2019 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 482 increasing their positions, 665 reducing their positions, and 154 closing their positions.
2.07% more ownership
Funds ownership: 75.6% → 77.67% (+2.1%)
6% less funds holding
Funds holding: 1,605 → 1,516 (-89)
18% less capital invested
Capital invested by funds: $102B → $83.5B (-$18B)
19% less call options, than puts
Call options by funds: $434M | Put options by funds: $534M
28% less repeat investments, than reductions
Existing positions increased: 482 | Existing positions reduced: 665
43% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 154
49% less funds holding in top 10
Funds holding in top 10: 49 → 25 (-24)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$851M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$457M |
| 3 |
Renaissance Technologies
New York
|
+$187M |
| 4 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$184M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$177M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.64B |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$685M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$574M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$397M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$300M |
LLY Hedge Fund Activity: Q2 2019 in Review
1,516 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q2 2019, worth a combined $83.5B — down 18% from $102B a quarter earlier.
Sellers outnumbered buyers: 154 funds closed out of LLY and 88 opened new positions — a net loss of 66 holders — while 665 trimmed existing stakes and 482 added.
The largest buyer was Nuveen, adding an estimated $851M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.64B.
- 1,516 institutional investors held Eli Lilly (LLY) as of Q2 2019, down from 1,605 in Q1 2019.
- Funds reported $83.5B of Eli Lilly stock for Q2 2019, down 18% quarter-over-quarter.
- 88 funds opened new Eli Lilly positions in Q2 2019 and 154 closed out, a net change of -66 holders.
- The largest Eli Lilly buyer in Q2 2019 was Nuveen, an estimated $851M added.
- The largest Eli Lilly seller in Q2 2019 was T. Rowe Price Associates, an estimated $1.64B sold.
Based on aggregated 13F filings for Q2 2019.